Literature DB >> 33175302

The "fixed" SPECT MPI defect: Where are we and where should we be going?

Henry Gewirtz1.   

Abstract

This brief review focuses on reasons why myocardial perfusion imaging (MPI) SPECT defects may appear "fixed" (rest vs stress). A combination of technical and physiology factors are responsible in most cases and are discussed. Perhaps the major reason defects will appear fixed is that there is no absolute quantitative measurement of myocardial blood flow (MBF, rest and stress) with which to assess the magnitude and potential direction of change in the defect vs reference zone with stress. Cardiac PET MPI provides absolute measurements of MBF required to understand the clinical significance of the SPECT "fixed" defect and are highlighted. Emphasis is given to use of the actual MBF measurements though indexing stress MBF to that of truly normal subjects (RFR or FFRPET) will prove useful in recognition of multi-vessel CAD. The availability of 18F flurpiridaz for clinical use is likely to encourage more widespread adoption of cardiac PET MPI for evaluation of patients with known or suspected CAD.

Entities:  

Mesh:

Year:  2020        PMID: 33175302     DOI: 10.1007/s12350-020-02434-4

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  3 in total

1.  Pathophysiology of chronic myocardial hibernation.

Authors:  H Gewirtz
Journal:  Circulation       Date:  1997-08-05       Impact factor: 29.690

Review 2.  Role of thallium-201 and PET imaging in evaluation of myocardial viability and management of patients with coronary artery disease and left ventricular dysfunction.

Authors:  J Maddahi; H Schelbert; R Brunken; M Di Carli
Journal:  J Nucl Med       Date:  1994-04       Impact factor: 10.057

3.  Myocardial metabolism of fluorodeoxyglucose compared to cell membrane integrity for the potassium analogue rubidium-82 for assessing infarct size in man by PET.

Authors:  K L Gould; K Yoshida; M J Hess; M Haynie; N Mullani; R W Smalling
Journal:  J Nucl Med       Date:  1991-01       Impact factor: 10.057

  3 in total
  1 in total

1.  Phase I clinical study of NMB58, a novel positron emission tomography (PET)-myocardial perfusion imaging tracer, conducted to evaluate its safety and pharmacokinetics in Japanese healthy adult males.

Authors:  Mirai Kawano; Junichi Tsuchiya; Hyeyeol Bae; Koichiro Kimura; Kota Yokoyama; Marie Takahashi; Makiko Honda; Masato Tominaga; Ukihide Tateishi
Journal:  Ann Nucl Med       Date:  2021-03-01       Impact factor: 2.668

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.